1. AB0038 Tbk1: a key regulator and potential treatment target for interferon positive systemic lupus erythematosus and systemic sclerosis. (12th June 2018) Authors: Huijser, E.; Bodewes, I.; van Helden-Meeuwsen, C.; Tas, L.; Huizinga, R.; Dalm, V.; van Hagen, M.; Groot, N.; Kamphuis, S.; van Daele, P.; Versnel, M. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 1219 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AB0145 EFFECTS OF IMMUNOSUPPRESSIVE MEDICATION ON TYPE I INTERFERON ACTIVATION: IN VITRO ANALYSIS SHOWS A DOWNREGULATING EFFECT ON IFN ACTIVATION OF HYDROXYCHLOROQUINE AND ASPIRIN. (13th June 2020) Authors: Wahadat, M. J.; Lourens, M.; Huijser, E.; Van Helden-Meeuwsen, C. G.; Kamphuis, S.; Versnel, M. Journal: Annals of the rheumatic diseases Issue: Volume 79(2020)Supplement 1 Page Start: 1373 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. FRI0307 Tbk1 inhibition downregulates expression of interferon type i and the upregulated expression of rig-like receptors and dna-sensing receptors in interferon positive primary sjÖgren's syndrome patients. (12th June 2018) Authors: Bodewes, I.; Huijser, E.; van Helden-Meeuwsen, C.; Tas, L.; Huizinga, R.; Dalm, V.; van Hagen, M.; Groot, N.; Kamphuis, S.; van Daele, P.; Versnel, M. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 690 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗